Literature DB >> 16122961

Effects of the peroxisome proliferator-activated receptor-gamma co-activator-1 Gly482Ser variant on features of the metabolic syndrome.

Marie-Claude Vohl1, Alain Houde, Stéphan Lebel, Frédéric-Simon Hould, Picard Marceau.   

Abstract

Factors influencing the severity of the metabolic syndrome among obese subjects or the conversion to cardiovascular disease or type 2 diabetes (T2D) remain largely unknown, but there is strong evidence for genetic susceptibilities. Peroxisome proliferator-activated receptor-gamma co-activator-1 (PPARGC1) is a transcriptional co-activator of many nuclear receptors including PPAR-gamma, involved in the regulation of fatty acid oxidation, skeletal muscle fiber type specificity, and gluconeogenesis. Given the critical role of PPARGC1, it becomes a promising candidate gene for the metabolic syndrome and T2D. This study aimed to investigate whether genetic variations in human PPARGC1 gene are associated with metabolic syndrome-related phenotypes and T2D among obese subjects. Molecular screening of the PPARGC1 gene in 24 morbidly obese French-Canadians revealed 13 variants. Eight genetic variations were in introns: c.55-27T>A, c.234+52C>A, c.553-40A>G, c.553-11T>C, c.757+161T>C, c.1793+19C>G, c.2141+192G>A, and c.2293+146A>G, and five were in coding regions: Thr394Thr, Asp475Asp, Gly482Ser, Thr528Thr, and Thr612Met with a relative allele frequency of 18.5, 5.2, 37.0, 42.5, and 6.8%, respectively. Thr394Thr, Asp475Asp, and Thr528Thr were in linkage disequilibrium with the Gly482Ser variant, the only non-synonymous variant with a relative allele frequency of more than 10%. Association studies were performed with the Gly482Ser variant. In non-diabetics, we compared between genotype differences in metabolic syndrome-related traits (waist girth, SBP, DBP, triglycerides, HDL-cholesterol (C), and fasting glucose levels). There was a difference in mean plasma HDL-C concentrations, the Gly/Gly group had lower concentrations than the Gly/Ser group (P<0.05). These results suggest that the Gly482Ser polymorphism may explain some of the between-obese variance observed in metabolic syndrome-related traits.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16122961     DOI: 10.1016/j.ymgme.2005.07.002

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  14 in total

1.  A polymorphism of the interferon-gamma-inducible protein 30 gene is associated with hyperglycemia in severely obese individuals.

Authors:  V Turcot; L Bouchard; G Faucher; A Tchernof; Y Deshaies; L Pérusse; P Marceau; F S Hould; S Lebel; Marie-Claude Vohl
Journal:  Hum Genet       Date:  2011-06-24       Impact factor: 4.132

2.  Effect of Peroxisome Proliferator-Activated Receptor-γ Coactivator-1 Alpha Variants on Spontaneous Clearance and Fibrosis Progression during Hepatitis C Virus Infection in Moroccan Patients.

Authors:  Raouia ElFihry; Mohcine Elmessaoudi-Idrissi; Fatima-Zahra Jadid; Imane Zaidane; Hajar Chihab; Mohamed Tahiri; Mostafa Kabine; Wafaa Badre; Isabelle Chemin; Agnes Marchio; Pascal Pineau; Sayeh Ezzikouri; Soumaya Benjelloun
Journal:  Virol Sin       Date:  2020-04-15       Impact factor: 4.327

3.  PPARGC1A sequence variation and cardiovascular risk-factor levels: a study of the main genetic effects and gene x environment interactions in children from the European Youth Heart Study.

Authors:  E C Brito; K S Vimaleswaran; S Brage; L B Andersen; L B Sardinha; N J Wareham; U Ekelund; R J F Loos; P W Franks
Journal:  Diabetologia       Date:  2009-01-29       Impact factor: 10.122

4.  THE PPARGC1A - GLY482SER POLYMORPHISM (RS8192678) AND THE METABOLIC SYNDROME IN A CENTRAL ROMANIAN POPULATION.

Authors:  K Csép; E Szigeti; M Vitai; L Korányi
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Apr-Jun       Impact factor: 0.877

5.  LINE-1 methylation in visceral adipose tissue of severely obese individuals is associated with metabolic syndrome status and related phenotypes.

Authors:  Valérie Turcot; André Tchernof; Yves Deshaies; Louis Pérusse; Alexandre Bélisle; Simon Marceau; Simon Biron; Odette Lescelleur; Laurent Biertho; Marie-Claude Vohl
Journal:  Clin Epigenetics       Date:  2012-07-02       Impact factor: 6.551

6.  The single nucleotide polymorphism Gly482Ser in the PGC-1α gene impairs exercise-induced slow-twitch muscle fibre transformation in humans.

Authors:  Peter Steinbacher; René G Feichtinger; Lyudmyla Kedenko; Igor Kedenko; Sandra Reinhardt; Anna-Lena Schönauer; Isabella Leitner; Alexandra M Sänger; Walter Stoiber; Barbara Kofler; Holger Förster; Bernhard Paulweber; Susanne Ring-Dimitriou
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

7.  Comparison of the dipeptidyl peptidase-4 gene methylation levels between severely obese subjects with and without the metabolic syndrome.

Authors:  Valérie Turcot; André Tchernof; Yves Deshaies; Louis Pérusse; Alexandre Bélisle; Picard Marceau; Frédéric-Simon Hould; Stéfane Lebel; Marie-Claude Vohl
Journal:  Diabetol Metab Syndr       Date:  2013-02-04       Impact factor: 3.320

8.  PGC-1alpha Thr394Thr and Gly482Ser variants are significantly associated with T2DM in two North Indian populations: a replicate case-control study.

Authors:  Audesh Bhat; Anil Koul; Ekta Rai; Swarkar Sharma; M K Dhar; R N K Bamezai
Journal:  Hum Genet       Date:  2007-03-28       Impact factor: 5.881

9.  The PPARGC1A Gly482Ser polymorphism is associated with left ventricular diastolic dysfunction in men.

Authors:  Erik Ingelsson; Louise Bennet; Martin Ridderstråle; Marianne Söderström; Lennart Råstam; Ulf Lindblad
Journal:  BMC Cardiovasc Disord       Date:  2008-12-11       Impact factor: 2.298

10.  The Gly482Ser genotype at the PPARGC1A gene and elevated blood pressure: a meta-analysis involving 13,949 individuals.

Authors:  Karani Santhanakrishnan Vimaleswaran; Jian'an Luan; Gitte Andersen; Y Li Muller; Eleanor Wheeler; Ema C Brito; Stephen O'Rahilly; Oluf Pedersen; Leslie J Baier; William C Knowler; Inês Barroso; Nicholas J Wareham; Ruth J F Loos; Paul W Franks
Journal:  J Appl Physiol (1985)       Date:  2008-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.